• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ: REGN )

    824.48 +7.83 (+0.96%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Regeneron Pharmaceuticals

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    41 42 Next >
    Assessing Regeneron Pharmaceuticals's Performance Against Competitors In Biotechnology Industry
    Via Benzinga
    3 Recession-Resistant Stocks: Low Beta, High Margins, Low Debt
    Check out these three stocks with financial metrics showing recession resistance and underlying business dynamics to back them up. 
    Via MarketBeat
    Topics Bankruptcy Bonds Economy
    Exposures Debt Markets Economy Financial
    Is It Time to Buy October's Worst-Performing Nasdaq Stocks?
    Is it a good time to scoop up last month's biggest losers? Check out October's largest price drops on the Nasdaq, and see whether any of them look like good buys today. 
    Via The Motley Fool
    Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    This Is What Whales Are Betting On Regeneron Pharmaceuticals
    Via Benzinga
    Regeneron Earnings Top Views For Biotech Giant
    Shares of the biotech giant have been in a sharp slide. 
    Via Investor's Business Daily
    $100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 Today
    Via Benzinga
    Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say
    Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
    Via Benzinga
    Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
    A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
    Via Talk Markets
    Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    From Glancy Prongay & Murray LLP
    Via Business Wire
    INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    From Law Offices of Howard G. Smith
    Via Business Wire
    A Closer Look at 23 Analyst Recommendations For Regeneron Pharmaceuticals
    Via Benzinga
    Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
    Via Benzinga
    The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
    The major indexes declined, but haven't fallen apart. 
    Via Investor's Business Daily
    Market Whales and Their Recent Bets on REGN Options
    Via Benzinga
    What the Options Market Tells Us About Regeneron Pharmaceuticals
    Via Benzinga
    Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?
    Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, Libtayo, and Dupixent drives performance. 
    Via Benzinga
    Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
    Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices in nearly two months. 
    Via Benzinga
    Regeneron Reports Third Quarter 2024 Financial and Operating Results
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
    Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
    Via Benzinga
    EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss
    EyePoint Pharmaceuticals' shares rise as interim Phase 2 VERONA trial data shows Duravyu improves visual acuity and anatomy in diabetic macular edema patients. 
    Via Benzinga
    Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
    One of these players has split its stock in the past. The other one hasn't. 
    Via The Motley Fool
    Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent
    Eli Lilly's Ebglyss improves skin and itch symptoms in eczema patients, including Dupixent-treated cases, with positive Phase 3b ADapt study results shared. 
    Via Benzinga
    Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Seagate To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
    There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
    Via Talk Markets
    Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Healthcare Sector Update: Life in the Slow Lane while we wait for BIOTECH Bounce
    Healthcare sector lags despite moderate growth. Note bad news from CVS and Humana. 
    Via Talk Markets
    Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    41 42 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.